No Way Home & Morbius Proved The Spider-Man MCU Deal's Flaw
The opposite box office results of Spider-Man: No Way Home and Morbius perfectly exemplify the biggest flaw in the Marvel and Sony Spider-Man deal. While not much has been heard yet about Spider-Man 4, including if Jon Watts will return or not, the Spider-Man franchise continues on the big screen as Morbius was released, and Kraven The Hunter, Madame Web, and El Muerto are all on different stages of production. The Tom Holland Spider-Man movies and the villains' spin-offs, however, have a major difference in terms of production – one that helps explains why the MCU's Spider-Man films are much better received.
From Sam Raimi's first Spider-Man to The Amazing Spider-Man 2, every Spider-Man film was made under the total creative control of Sony. The studio had bought the Spider-Man movie rights in 1999, and from then on, the Marvel character became one of Sony's flagships. However, after The Amazing Spider-Man 2's underwhelming results and the constant comparison with how successful the MCU had become despite not having the right to some of Marvel's most important characters, Sony and Marvel Studios reached a surprising agreement to have a Spider-Man franchise co-produced by both studios. Andrew Garfield was recast as Spider-Man, and Tom Holland starred as a brand new version of the character in Captain America: Civil War.
Related: Sony's Spider-Man Movie Failure Is Secretly Good News For Garfield's Return
While the Sony and Marvel deal made it so that Spider-Man could finally interact with other heroes on the big screen, there is still a lack of synergy in how the Spider-Man IP is being developed. More especially, while the Spider-Man: Homecoming trilogy was helmed by Marvel Studios' creative team led by Kevin Feige, the
Read more on screenrant.com
